Navigation Links
Bioheart Makes Breakthrough in Critical Limb Ischemia Therapy with Stem Cells Obtained from Fat Tissue
Date:12/21/2009

SUNRISE, Fla., Dec. 21 /PRNewswire-FirstCall/ --

www.bioheartinc.com

The Bioheart adipose derived stem cells treatment "ASCs Treatment":

  • A large quantity of stem cells can be obtained from a patient's fat (adipose) tissue without pain and other side effects, quickly and cheaply.
  • Adipose stem cells are capable of promoting blood vessel formation and assisting with the healing of damaged blood vessels.
  • Lower limb ischemia is pain, often severe enough to be intolerable, in the lower limb due to limited or inefficient blood circulation.
  • Diabetic patients, globally, are fifteen times more susceptible to limb amputation as a result of lower limb ischemia than other patients. These patients can now be treated using the new therapy.

Bioheart, Inc. (OTC Bulletin Board: BHRT) offers yet another medical breakthrough with the next-level stem cell treatment for critical limb ischemia patients. The stem cells aid in promoting angiogenesis or the formation of new blood vessels and providing support for the healing of damaged blood vessels.

Bioheart, in collaboration with University Hospital Ostrava in the Czech Republic, has already begun treating patients with critical limb ischemia utilizing ASCs. Bioheart is working to place the TGI systems throughout the Czech Republic for a variety of other indications including acute myocardial infarction and chronic heart ischemia, developing new and special treatment plans for patients with these heart issues.

Dr. Karl Groth, Bioheart's Chairman and CEO commented on the therapy: "Stem cell therapy is not just intended as a temporary solution, but it is developed as a novel therapy allowing nat
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Bioheart Inc. to Participate in the 2009 World Stem Cell Summit on September 23rd
2. Bioheart Strengthens Executive Team in Order to Accelerate Business Plan and Enhance Its Position in the Cardiovascular Stem Cell Therapy Industry
3. United States FDA Clears the REGEN Trial to Test Biohearts Combination Gene and Stem Cell Therapy in Heart Failure Patients
4. Bioheart, Inc. Announces Additional Funding Support
5. Bioheart, Inc. to Present at Red Chip Investor Conference in New York
6. Bioheart, Inc., Announces Letter of Intent to Acquire MEDICALGORITHMICS, Ltd.
7. Bioheart, Inc. Announces Financial Results for Second Quarter 2008
8. Bioheart, Inc. Announces Results of Annual Meeting
9. Bioheart, Inc., Announces Management Change
10. Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients
11. Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... ... Inc. Magazine released its annual list of the 5,000 fastest-growing privately held ... the three years through 2014. Being named to the Inc. 5000 list designates a ... , “We are thrilled to make the Inc. 5000 list for 2015,” stated ...
(Date:8/26/2015)... Aug. 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended June 30, ... Canadian dollars and presented under International Financial Reporting ... with respect to our Oral Amp B program, ... manufacturer," said Andrew Rae , President & ...
(Date:8/26/2015)... 26, 2015 Intrexon Corporation (NYSE: XON ... closing of its previously announced public offering of common ... of their option to purchase an additional 731,707 shares ... $41.00 per share.  The exercise of the underwriters, option ... sold by Intrexon to 5,609,756 shares and increased the ...
(Date:8/26/2015)... ... August 26, 2015 , ... PRC Clinical, a Clinical ... relationships with local sponsors in southern California. The Clinical Trial Management Expert CRO seeks ... and regulatory pathways., , Stem Cell Meeting on the ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... to video screens, Eau Claire-based entrepreneur Mike Strand ... , ,A former technology consultant for Delta Technology and Cray ... founded StrandWare Inc. , a company based out of ... sold the company in 2001, it had expanded into a ...
... Income from continuing operations at Milwaukee-based Rockwell Automation Inc. for ... 90 percent leap from the $74.9 million the company earned ... quarter of 2005, including discontinued operations, was an even $150 ... that, Rockwell shares fell off the table, dropping more than ...
... the British Consulate-General, which is looking to expand ... companies on Tuesday for a luncheon to explore ... with complimentary products or complimentary technologies," said Frank ... of the British Consulate-General . "Oftentimes the partnership ...
Cached Biology Technology:Online Kiosks founder Mike Strand uses contest to screen new business plan 2Online Kiosks founder Mike Strand uses contest to screen new business plan 3British, Wisconsin firms explore life-science opportunities together 2British, Wisconsin firms explore life-science opportunities together 3
(Date:8/5/2015)... MOUNTAIN VIEW, Calif. , Aug. 5, 2015 /PRNewswire/ ... it exhibits continuous growth in applications, penetration into newer ... year after year. The global biosensors space has seen ... having exited the market so far. (Photo ... from Frost & Sullivan, Analysis of the Global ...
(Date:8/4/2015)... 2015  AMRI (NASDAQ: AMRI ) today reported financial and ... Highlights: , Second quarter contract revenue of ... , Adjusted contract margins of 26 % ... a $0.05 decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial ...
(Date:7/31/2015)... Den 10. internationale konference om Genomik (ICG-10, ... - 25. oktober i Shenzhen , ... i år. Siden starten i 2006 er ICB blevet ... og er en af de mest dynamiske, entusiastiske og ... nylige gennembrud og fremskridt inden for ,omik,-forskning, som yderligere ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... the Journal of Antimicrobial Chemotherapy1 provides the best ... (CDI)---one of the most common and increasing types ... if doctors prescribe narrow-spectrum antibiotics rather than broad-spectrum ... Hospital in London, which now has the lowest ...
... plays a major role in deadly prion diseases by ... "seeds" that allow fatal brain illnesses to quickly spread, ... exciting, researchers say, because they might reveal a way ... If a drug could be made that inhibits this ...
... bird flu, involving the use of a mathematical model, ... be the best way to deal with an emerging ... a worldwide human epidemic yet because it rarely passes ... would take 6-8 months to develop a vaccine effective ...
Cached Biology News:Reminding doctors which antibiotics to prescribe cuts C. difficile infection rates 2Reminding doctors which antibiotics to prescribe cuts C. difficile infection rates 3Reminding doctors which antibiotics to prescribe cuts C. difficile infection rates 4Brown team finds crucial protein role in deadly prion spread 2
Thermal printer paper is used with the thermal printer for the VersaFluor fluorometry systems. Supplied as 10 rolls....
The thermal printer, 120 V, is used to record fluorescence data acquired with the VersaFluor fluorometry systems. The printer includes a cable and power adaptor....
... Leu-CMK FLISP Assay with SR-101 Labeled ... nm) • Accurately measure serine protease ... permeabilization • B-Bridge's FLISP Kits utilize ... proteases (FLISPs) to measure chymotrypsin-like activity ...
... systems, known as ChemiArrayTM Mouse Cytokine ... with current methodologies. Besides the ability ... present a more accurate reflection of ... detect secreted cytokines, and no amplification ...
Biology Products: